Article
A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.
Molecular cancer research : MCR - 1 Aug 2010
Geretti Elena, van Meeteren Laurens A, Shimizu Akio, Dudley Andrew C, Claesson-Welsh Lena, Klagsbrun Michael
Abstract excerpt
Neuropilins (NRP1 and NRP2) are coreceptors for vascular endothelial growth factor (VEGF) and mediate angiogenesis and tumor progression. VEGF binds to the NRP1 and NRP2 B domains. Previously, it was shown that mutagenesis of the soluble NRP2 B domain (MutB-NRP2) increased affinity to VEGF by 8-fold. Here, we show that MutB-NRP2 inhibited (125)I-VEGF binding to NRP1, NRP2, and VEGFR-2. It antagonized VEGF-induced...
Topics
- Animals
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Aorta
- Bevacizumab
- Cells, Cultured
- Embryonic Stem Cells
- Endothelium, Vascular
- Female
- Fluorescent Antibody Technique
- Humans
- Melanoma
- Mice